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Background: Human rhinoviruses, major precipitants of asthma exacerbations, induce lower airway inflammation
and mediate angiogenesis. The purpose of this study was to assess the possibility that rhinoviruses may also
contribute to the fibrotic component of airway remodeling.
Methods: Levels of basic fibroblast growth factor (bFGF) mRNA and protein were measured following rhinovirus
infection of bronchial epithelial cells. The profibrotic effect of epithelial products was assessed by DNA synthesis
and matrix metalloproteinase activity assays. Moreover, epithelial cells were exposed to supernatants from cultured
peripheral blood mononuclear cells, obtained from healthy donors or atopic asthmatic subjects and subsequently
infected by rhinovirus and bFGF release was estimated. bFGF was also measured in respiratory secretions from
atopic asthmatic patients before and during rhinovirus-induced asthma exacerbations.
Results: Rhinovirus epithelial infection stimulated mRNA expression and release of bFGF, the latter being positively
correlated with cell death under conditions promoting rhinovirus-induced cytotoxicity. Supernatants from infected
cultures induced lung fibroblast proliferation, which was inhibited by anti-bFGF antibody, and demonstrated
increased matrix metalloproteinase activity. Rhinovirus-mediated bFGF release was significantly higher in an in vitro
simulation of atopic asthmatic environment and, importantly, during rhinovirus-associated asthma exacerbations.
Conclusions: Rhinovirus infection induces bFGF release by airway epithelium, and stimulates stroma cell
proliferation contributing to airway remodeling in asthma. Repeated rhinovirus infections may promote asthma
persistence, particularly in the context of atopy; prevention of such infections may influence the natural history
of asthma.
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Structural changes in the asthmatic lung, collectively
known as airway remodeling, are now widely recognized
and potentially associated with bronchial hyperrespon-
siveness, the incomplete therapeutic effect of corticoster-
oids, as well as the progressive decline of pulmonary
function in asthmatic patients with more severe and
chronic disease. Increased myofibroblast proliferation
and subepithelial collagen deposition, wall thickening
and angiogenesis are important components of airway* Correspondence: cskevaki@allergy.gr
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reproduction in any medium, provided the orremodeling [1]. Numerous studies pinpointed the central
role of the bronchial epithelium in these processes [2],
exemplified by its ability to release potent modulators of
collagen turnover and fibroblast proliferation, including
cytokines, growth factors, as well as matrix metallopro-
teases (MMP) [3-5].
The multifunctional basic fibroblast growth factor
(bFGF or FGF-2) is a potential mediator of airway
remodeling due to its ability to regulate migration and/
or proliferation of vascular endothelial cells, fibroblasts,
airway smooth muscle cells and myofibroblasts [6].
Indeed, bFGF is increased in the bronchoalveolar lav-
age (BAL) fluid of patients with asthma and further up-
regulated upon allergen challenge [7]. Furthermore, theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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correlates with the number of cells expressing bFGF [8].
The asthmatic epithelium is a major source of bFGF [9].
Chemical or mechanical insult to the epithelium may
lead to proliferation of myofibroblasts and increased
collagen production due to the action of growth factors
including bFGF [10]. Viral respiratory tract infections
trigger acute asthma exacerbations, human rhinoviruses
(RV) being the most frequent agent [11]. RVs infect and
replicate in the lower airway epithelium [12], leading to
local and systemic immune responses and production
of inflammatory mediators [13], that have the potential
of inducing and/or regulating airway remodeling [14].
We have recently demonstrated that RV infection may
promote airway remodeling by inducing angiogenesis
through vascular endothelial growth factor (VEGF) pro-
duction by the bronchial epithelium [15].
Based on the above, we hypothesized that RV infection
may also contribute to the fibrotic component of airway
remodeling through bFGF, which may induce fibro-
blast proliferation and regulate collagen turnover. We
assessed the ability of RV to stimulate bFGF release by
human bronchial epithelium in vitro, evaluated the
impact of the released bFGF on pulmonary fibroblast pro-
liferation and measured the activity of MMP in superna-
tants of RV-infected bronchial epithelial cells. Moreover,
we estimated the influence of the atopic asthmatic envir-
onment on bFGF release, as well as the abundance of
bFGF in vivo during RV-associated asthma exacerbations.
Methods
Cell cultures
Human bronchial epithelial cells (BEAS-2B) (ECACC,
Salisbury, UK) were grown as described [12,13]. Normal
human bronchial epithelial (NHBE) cells were obtained
from Clonetics, Wokingham, UK and derived from nor-
mal non-smoking adult donors. Primary human bronchial
epithelial (PHBE) cells were derived from an adult volun-
teer without asthma after informed written consent and
approval by the ‘Sotiria’ Hospital Review Board for
Human Studies. PHBE and NHBE cells were grown in
bronchial epithelial basal medium (BEBM), which was
supplemented with growth supplements as recommended
by the manufacturer, and they were used at passages 2–3.
Primary cultures of normal human lung fibroblasts
were developed using the explant method [16], from ap-
parently normal areas of the lungs of consenting volun-
teers undergoing surgery [17]. The human lung
fibroblast strain CCD19Lu was purchased from ECACC.
All fibroblasts were routinely cultured in Minimal Essen-
tial Medium (MEM) supplemented with 10% Fetal
Bovine Serum (FBS). Primary cultures were used between
passages 3 and 6. Harvesting by trypsinization and cell
counting were performed as previously described [16].All cells were tested periodically and were found to be
mycoplasma-free.
Virus cultures and titration
Major and minor rhinoviruses (RV16 and RV1b, respect-
ively) were propagated in Ohio-HeLa cells (ECACC) at
33°C in a humidified 5% CO2 incubator, as previously
described [12]. Briefly, upon development of full cyto-
pathic effect (CPE), cells and supernatants were har-
vested, frozen and thawed, clarified by centrifugation,
aliquoted and stored at −70°C. Lysates of parallel Ohio-
HeLa cell cultures, not infected with virus, were used as
controls in subsequent experiments. In order to deter-
mine RV titres, Ohio-HeLa cells were seeded in 96-well
plates until 60-70% confluence at the time of infection.
Logarithmic dilutions of RVs were made in multiple
wells and the plates were fixed and stained after five days
with 5% formaldehyde, 5% ethanol and 0.1% crystal vio-
let in PBS. The end-point titer was defined as the high-
est dilution at which a CPE was detected in at least half
of the wells and expressed as the inverse logarithm of
this dilution.
Epithelial cell infection and collection of conditioned
media (CM)
Low passage (10–19) BEAS-2B cells were grown and
infected by RV1b as described [12,13], at multiplicity
of infection (MOI) of 1, unless otherwise specified. For
the fibroblast proliferation assay, BEAS-2B cells were
infected with RV1b under serum-free conditions, in
order to eliminate any direct effect of the serum con-
tained in supernatants on the proliferation of the stroma
cells. For the experiments involving exposure of BEAS-
2B cells to an atopic environment, we used pooled
supernatant from peripheral blood mononuclear cells
(PBMC), which were obtained by healthy donors and
atopic asthmatic subjects and infected by RV1b in vitro
in the course of a recently published study, as described
[18]. Briefly, 0.6 mL of PBMC supernatant was added
per well of epithelial cells and left for 24 h at 37°C, at
which time it was removed and BEAS-2B were infected
with RV1b at MOI 1.
Supernatants (conditioned media, CM) were collected
48 h after infection (unless otherwise specified), clarified
by centrifugation (10 min/3000 g/4°C), and stored at
−70°C until used in immunoassays. Control CM were
collected from parallel cultures exposed to heat-
inactivated RV1b (1 h at 58°C), ultraviolet radiation
(UV)-inactivated RV1b (4 cm from a 100 W UV light
source for 8 min) or HeLa cell lysates. Heat and UV in-
activation of RV1b was effective as assessed by titration
assays. Moreover, in some experiments, an anti-human
VEGF antibody (R&D Systems, Europe) was added to
BEAS-2B after RV1b infection at final concentrations
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CM were UV irradiated in order to inactivate possible
residual RV1b, and thus eliminate any direct RV1b effect
on fibroblast proliferation. UV irradiation did not result
in significant alterations on bFGF levels as assessed
by ELISA performed before and after UV irradiation
of CM.
Cytotoxicity assay
RV-induced cytotoxicity on BEAS-2B cells was mea-
sured using a colorimetric assay, as previously described
[19]. Epithelial cells were plated in 48-well plates in ser-
ial dilutions and allowed to grow for 48 h, reaching con-
fluence of 100%, 50%, 25% and 12,5%. 48 h after
incubation with RV1b or control medium, cells were
washed twice in PBS and a volume of crystal violet stain-
ing buffer equal to the 1/5th of the original culture
medium was added to the wells as indicator of cell via-
bility [20,21].
Cells were incubated for 30 min at room temperature
followed by extensive washing with distilled water. After
air drying, 0.2 ml of a destain buffer (16.6% v/v glacial
acetic acid, 50% v/v methanol in ultra pure water) was
added to the wells for 5 min. Cells were fully destained
and the produced color was transferred to a clear 96
well ELISA plate and optical density was measured with
a photometer at 595 nm (Ceres 90°C, Bio-Tec Instru-
ments, Inc, Winooski VT, USA) [12]. Cytotoxicity was
estimated as % of the negative control (1- O.D RV
infected/ O.D HeLa * 100).
DNA synthesis assay
The effect of epithelial cell CM on human lung fibroblast
proliferation was estimated using tritiated thymidine
incorporation into newly synthesized DNA, essentially as
described [22]. Medium supplemented with 2 ng/ml
human recombinant bFGF (R&D Systems Europe) served
as a positive control. In order to neutralize bFGF-activity,
media conditioned by epithelial cells or media supple-
mented with recombinant bFGF were preincubated with
a goat anti-bFGF neutralizing antibody (R&D Systems
Europe) at a final concentration of 10 μg/ml for 60 min
at 37°C. Control experiments with total goat IgG indi-
cated no interference with this DNA synthesis assay
(data not shown).
MMP activity assay
Conditioned media derived from RV1b-infected or control
epithelial cells were mixed at a 1:1 ratio with MMP-
incubation buffer 50 mM Tris (pH: 7.6), 150 mM NaCl,
10 mM CaCl2, 1 μM ZnCl2 containing the fluorogenic
substrate Dabcyl-Gaba-Pro-Gln-Gly-Leu-Glu-(EDANS)-
AIa-Lys-NH2 (TNO211, Calbiochem) at a final concentra-
tion 7 μM [23]. This peptide contains the MMP-cleavablebond Gly-Leu, as well as the fluorophore EDANS, whose
fluorescence is quenched by the close proximity of Dabcyl.
After enzymatic cleavage the quenching is eliminated and
fluorescence is detectable. The catalytic efficiency of
TNO211 is very high for MMP-9 (kcat/Km=619,000
M-1 s-1), MMP-2 (kcat/Km=206,000 M-1 s-1), MMP-3
(kcat/Km=40,000 M-1 s-1), and MMP-1 (kcat/Km=21,000
M-1 s-1) [23]. In the experiments presented herein, after in-
cubation of the TNO211-supplemented conditioned media
at 37°C in the dark for 3 h, fluorescence emission was
counted at 480 nm after excitation at 340 nm, using a Fluos-
tar Galaxy microplate reader (BMG Labtechnologies,
Offenburg, Germany)
Nasopharyngeal wash samples
Samples from 10 atopic children (6 boys, mean age
10.7 years, range 8–16) with intermittent or mild persist-
ent asthma according to the GINA guidelines and posi-
tive skin prick tests (SPT) to at least 1 of a panel of
locally relevant allergens, obtained in the course of a
prospective clinical study conducted at the “P&A
Kyriakou” Children’s Hospital and approved by the
hospital’s Review Board, had been collected after
informed written consent of surrogates at a symptom-
free period and subsequently during an RV-associated
asthma exacerbation. The presence of RV (and its ab-
sence at baseline), as well as the absence of respiratory
syncytial virus (RSV), corona, adeno-, influenza A and B
and parainfluenza viruses in the nasopharyngeal washes
during the exacerbations was assessed by RT-PCR [24].
ELISA assays
Levels of bFGF were measured in cell supernatants
using a commercially available sandwich ELISA assays
(R&D Systems, Europe) according to the manufacturer’s
instructions. The lower detectable level was 3 pg/ml.
Nasopharyngeal wash samples were treated with hep-
arin in order to increase release from heparin sulphate
binding sites as described in Shute et al. [9]. Briefly,
heparin (Sigma Chemical Co) was added to the samples at
a final concentration of 100 μg/ml and samples were incu-
bated for one hour at 37°C. Following incubation, bFGF
that had been released and captured by the primary anti-
body was quantified by completing the subsequent ELISA
steps according to the manufacturer’s instructions.
RT-PCR analysis
cDNA was prepared from RV1b-infected and HeLa
lysate-exposed BEAS-2B cells, which were infected
under conditions not allowing virus mediated cytotox-
icity, ie high cell culture density. Subsequently, cDNA
was subjected to semiquantitative RT-PCR against b-
actin as applied in our previous work focusing on RV-
mediated VEGF production [15]. bFGF-specific PCR
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TTC-AAG-G-3 and 50-GCA-CAC-ACT-CCT-TTG-ATA
GAC-ACA-A-30) and the predicted amplicon length
was 180 bp.Data and Statistical analysis
Distribution normality was assessed by the Kolmogorov-
Smirnov test. Data are expressed as means ± SEMs.
Comparisons between two groups were performed with
independent sample t-test. In the case of more groups,
one-way ANOVA with Bonferroni’s correction for
subsequent between-group effect evaluation was used. A
Wilcoxon signed-rank test was performed for comparing
bFGF levels in nasopharyngeal secretions of children
with atopic asthma at baseline to the respective levels
observed during an RV-associated asthma exacerbation.
Statistical analysis was conducted with Graph Pad Prism
3.0 software.Results
RV infection stimulates bFGF release by human bronchial
epithelial cells
Infection of NHBE cells with RV1b or RV16 at MOI 1
resulted in a significant induction of bFGF levels com-
pared to control (Figure 1A; p < .01 for RV1b and
p < .0001 for RV16). Similar results were obtained with
PHBE cells (data not shown).
We next used RV1b to infect BEAS-2B cells, a bron-
chial epithelial cell line extensively served as a well-
characterized in-vitro lower respiratory epithelium
model of RV infection [13,15,19]. Infection of BEAS-2B
cells resulted in a considerable (~10-fold) up-regulation
of bFGF release (233.3 ± 27.4 versus 23.1 ± 1.4 pg/ml for
control cultures; p < .001) by 48 h (Figure 1B). Exposure
of BEAS-2B cells to heat- or UV-inactivated RV1b did
not result in bFGF induction, suggesting that the effect
was virus-specific (Figure 1B; p < .001). Furthermore,
RV1b was shown to up-regulate bFGF release in a dose-
dependent manner (Figure 1C). Time-course experi-
ments showed that bFGF up-regulation initiated 24 h
following exposure to RV1b and reached its peak values
by 72 h (Figure 1D).RV infection upregulates bFGF transcription
We next asked whether the induction of bFGF release
reflected a preceding RV-mediated transcriptional acti-
vation. To this end, we used semiquantitative PCR, [15]
and showed that RV1b infection up-regulated bFGF
mRNA at both early (6 h) and late (24 h) time points
(Figure 1F) by 2.5- and 3.1-fold, respectively, further
suggesting that additional pathways may contribute to
the much higher induction observed at the protein level.RV-mediated bFGF release positively correlates to
RV-induced cytotoxicity
Cell death or injury have been identified as mechanisms
of extracellular release of preformed bFGF [25]. On the
other hand, we have recently shown that RV-induced
epithelial cytotoxicity may become considerable in a com-
promised, in terms of density, bronchial epithelium, as in
the case of asthma [19]. To assess the potential contribu-
tion of RV-mediated cytotoxicity on bFGF release by
bronchial epithelial cells, we infected the BEAS2B cells
with RV1b under conditions of high and low cytotoxicity
(sparse and dense cultures, respectively, with sparse cul-
tures roughly corresponding to the partially denuded
bronchial airway mucosa in asthma) and estimated the
bFGF that was subsequently released. We found that the
levels of secreted bFGF significantly correlated with RV-
mediated cytotoxicity (Figure 2; R2 = 0.91, p < .0001),
reaching up to 96-fold induction, implying that cell
death-associated bFGF release was an essential compo-
nent of RV1b-mediated production of this growth factor
by bronchial epithelial cells. Similarly, increased cytotox-
icity was correlated with increased bFGF secretion by
primary bronchial epithelial cells (data not shown).
VEGF promotes RV-mediated bFGF release
Based on the synergistic interaction of VEGF and bFGF
in the angiogenesis process and our previous finding that
RV infection induces VEGF production by bronchial epi-
thelial cells [15] we sought the possible involvement
of VEGF in bFGF release by the bronchial epithelium.
A neutralizing anti-human VEGF antibody was added
after RV1b infection of epithelial cells resulting in partial
inhibition of bFGF release. The inhibition was greater at
higher antibody concentrations (Figure 3; p < .01 for
0.1 μg/ml vs p < .001 for 5 μg/ml concentration).
RV epithelial infection stimulates lung fibroblast
proliferation, partly through bFGF
To assess the impact of RV-infection of bronchial epi-
thelial cells on stromal cells, UV-irradiated CM from
RV1b-infected and control BEAS-2B cultures were ap-
plied to serum-starved human CCD19Lu lung fibro-
blasts. RV1b-infected CM were able to stimulate the
proliferation of fibroblasts (34.9 ± 3.1% over control CM;
Figure 4; p < .001). These experiments were repeated
using primary cultures of normal human fibroblasts
with similar results (data not shown). To evaluate the
contribution of bFGF in the RV mediated stroma cell
proliferation, CM were incubated with neutralizing
concentrations of an anti-bFGF antibody. Antibody
treatment had no effect on control CM-mediated prolif-
eration, while it significantly suppressed proliferation
induced by RV1b-infected CM to 18.6 ± 3.1% over con-
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Figure 1 Rhinovirus (RV) infection induces bFGF release and mRNA expression in human bronchial epithelial cells. A, bFGF release by
normal human bronchial epithelial (NHBE) cells exposed to RV1b or HeLa lysate (control); *p < .01, **p < .0001. B, bFGF release by BEAS-2B
exposed to RV1b, heat-inactivated RV1b (hiRV), UV-inactivated RV1b (UVRV1b) or HeLa lysate (control); *p < .001. C, bFGF release by BEAS-2B
infected by RV1b at different MOIs; * p < .01, ** p < .001. D, Time course of bFGF release on infection by RV1b. * p < .01, ** p < .001, *** p < .0001.
For A, C and D, comparisons were made with cultures exposed to control medium. E, Relative abundance of bFGF mRNA in comparison to
β-actin after RV1b infection of BEAS-2B; *p < .05; **p < .01. n≥ 3 independent experiments.
Skevaki et al. Clinical and Translational Allergy 2012, 2:14 Page 5 of 11
http://www.ctajournal.com/content/2/1/14of the antibody; p < .01). Importantly, the residual activ-
ity of RV1b-infected CM in the presence of anti-bFGF
was not significantly higher than that of the control CM
in the presence of the antibody (13.9 ± 3.1%; p = .1295).
Similarly, the presence of the antibody significantly
inhibited fibroblast proliferation induced by recombinant
bFGF (2 ng/ml), serving as a positive control (Figure 4,
p < .001).
RV-infection up-regulates MMP activity released by
bronchial epithelial cells
To further examine the potential impact of RV-infection
on airway remodeling we measured the total activity of aseries of MMPs, in the CM of RV1b-infected epithelial
cells. We observed significantly increased MMP activity
released in the CM from RV1b-infected BEAS-2B, as
compared to control cultures (Figure 5; p < .05).
RV-induced bronchial epithelial bFGF release is more
pronounced in an atopic asthmatic as compared to the
non-atopic, non-asthmatic environment
We next asked whether the profibrotic response elicited
by RV infection is modulated under the influence of an
atopic asthmatic environment, as is the case with RV-
mediated VEGF induction [15]. To that end, CM of
RV1b infected-PBMCs, obtained by control subjects and














Figure 2 RV mediated bFGF release is correlated with
RV-induced cytotoxicity. Correlation of released bFGF with
RV1b induced cytotoxicity in sparse and dense cultures of BEAS-2B



































Figure 4 RV-infected epithelial cells stimulate fibroblast
proliferation, partially through bFGF. Conditioned media (CM)
from RV1b infected BEAS-2B cells significantly stimulated the
proliferation of quiescent human lung fibroblasts as compared to
CM of epithelial cells exposed to HeLa lysate (control). This
stimulation was partially suppressed following preincubation of
conditioned media with an anti-bFGF neutralizing antibody (Ab).
Medium supplemented with 2 ng/ml human recombinant bFGF
served as a positive control. (n = 5; NS: non-significant, *p < .01,
**p < .001).
Skevaki et al. Clinical and Translational Allergy 2012, 2:14 Page 6 of 11
http://www.ctajournal.com/content/2/1/14atopic asthmatic patients, respectively, were added to
BEAS-2B and the cells were further stimulated with
RV1b, as described [15,18]. CM from RV1b-infected
PBMCs rather than purified cytokines were used, to
better represent at relevant relative concentrations the
complex mixture of mediators resulting from the anti-
viral immune response [18]. Production of IFN-γ from
RV1b-stimulated PBMCs is significantly higher and IL-
10 production is lower in normal than in atopic asth-
matic subjects [18]. Moreover, RV infection results in a
significant upregulation of IL-8 and a statistically insig-
nificant increase of IL-6 production from PBMC, and a
parallel statistically insignificant TGF-β1 reduction in**
















Figure 3 Anti-VEGF antibody (Ab) suppresses RV mediated
bFGF induction. Partial suppression of RV1b induced bFGF release
in the presence of an anti-VEGF Ab in two different concentrations
(Ab1 = 0,1 μg/ml and Ab2= 5 μg/ml). (n = 3) (*p < .01 **p < .001).both atopic asthmatic and normal subjects [18]. These
CM were tested with RT-PCR for the presence of vRNA
before being added to BEAS-2B and were found to be
negative (data not shown). RV1b infected-PBMCs
released low levels of bFGF (median: 5.0 pg/ml). Most
importantly, PBMCs from subjects with asthma induced

























Figure 5 RV-infected epithelial cells demonstrate an increased
matrix metalloproteinase (MMP) activity. Conditioned media
(CM) from RV infected BEAS-2B cells demonstrate an increased MMP
activity using an assay detecting MMPs 2, 9, 3 and 1. (n = 3; *p < .05).

















Figure 7 bFGF levels in human airways during RV-associated
asthma exacerbations. Nasal aspirates were collected from 10
patients with asthma at a stable period (baseline) and subsequently,
during a virologically confirmed RV-associated asthma exacerbation.
bFGF levels were measured with ELISA. Horizontal bars represent
mean values (n=10; *P < .05).
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control subjects (Figure 6; p < .001).
BFGF levels are up-regulated in the airways during
RV-associated asthma exacerbations
To establish the relevance of the above findings in-vivo,
we measured bFGF in nasopharyngeal secretions of chil-
dren with atopic asthma at baseline and during a subse-
quent, virologically confirmed RV-associated asthma
exacerbation. bFGF levels significantly increased by ap-
proximately 5-fold in these patients during exacerbations
(Figure 7; 12.9 ± 4.1 pg/mL vs 64.3 ± 21.4 pg/mL; p < .05).
Notably, 3 among the 8 children that showed elevated
bFGF, demonstrated a dramatic up-regulation of bFGF
secretion (32 to 193-fold), whereas the rest 5 children
showed a more modest increase (1.3 to 6.6-fold). Yet, no
significant differences concerning lower airway symptom
scores or changes in lung function were recorded in our
study. Overall, RV infection during an asthma exacerba-
tion was indeed associated with increased bFGF secre-
tion in those patients.
Discussion
This is the first report of RV infection-mediated induc-
tion of lung fibroblast proliferation through increased
bFGF release by the bronchial epithelium. Moreover, to
our knowledge, this is the first time that RV-mediated
cytotoxicity is shown to affect the release of a cytokine
or growth factor by bronchial epithelial cells. We have
previously reported a time-dependent increase in virus

















Figure 6 Exposure to PBMC supernatant affects bFGF release
by bronchial epithelial cells. bFGF release by BEAS-2B cells
pre-exposed to supernatants from RV-infected PBMCs isolated from
atopic asthmatic (n = 3) or normal (n = 3) subjects and subsequently
infected with RV at MOI1 (*P < .001).as well as an RV-mediated bFGF release by such cells,
which was suppressed by anti-inflammatory treatment
in vitro [26]. In this study we extend and link these find-
ings demonstrating that RV-specific bFGF release is
time- and dose- dependent and results from both tran-
scriptional up-regulation and release from epithelial cells
upon induction of cytotoxicity. Activation of intracellular
protein kinases and signaling pathways may be respon-
sible for the transcriptional up-regulation of bFGF, as
has been recently demonstrated for RV-mediated VEGF
induction [27]; however, such investigations are beyond
the scope of this article. On the other hand, it is likely
that cell death-mediated pathways prevail over transcrip-
tional regulation, as the 20-fold increase in bFGF levels
at 48 h post-infection cannot be fully attributed to the
modest 2-fold increase of bFGF mRNA observed at
6 and 24 h post-infection. bFGF is constitutively pro-
duced from the epithelium of healthy lungs and its re-
lease may be induced by chemical or mechanical insult
to these cells [9]. In addition to the release of preformed
bFGF from extracellular storage sites, this molecule lacks
a conventional secretion signal and is being released
by various alternative pathways, including cell death
[25]. Epithelial cell desquamation is a central feature of
asthmatic airways, while RV-induced cytotoxicity may
become considerable in an already compromised epi-
thelium [19], suggesting that such mechanisms may
contribute to RV-mediated bFGF release by airway epi-
thelium, being of particular importance in asthma.
Respiratory syncytial virus infection may as well stimu-
late bFGF release, even in the presence of viral proteins
alone [28]. In contrast, RV replication was necessary for
enhanced bFGF release as evidenced upon use of heat-
or UV-inactivated RV. Despite virus replication, the
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among exposed cells [29] and differences in the degree
of infectivity may account for differences in levels of
bFGF release between cell types as reported in the
present and our previous study [26].
VEGF seems to play an important role in this process
as addition of anti-VEGF antibody resulted in partial
suppression of bFGF release. This is in agreement with
VEGF-mediated up-regulation of bFGF mRNA reported
in other in vitro cell injury settings [30]. Also, the use of
VEGF receptor inhibitors, both in vitro and in vivo,
blocked bFGF mediated angiogenesis, indicating that the
presence of VEGF is crucial in this process [31]. In fact,
VEGF and bFGF act synergistically in stimulating angio-
genesis and we have demonstrated RV mediated VEGF
induction in previous work [15]. In addition, TGF-β1
released by the RV-infected cells [16] may also mediate
bFGF release by extracellular deposits, as suggested by
studies with human pulmonary fibroblasts [17]. Potential
effects on bFGF expression by other cytokines, chemo-
kines and growth factors, which are known (or yet
unknown) to show increased production by bronchial
epithelial cells following RV infection [13,18,27,32,33]
cannot be excluded.
bFGF has been shown to induce cell proliferation in
quiescent cultures of human lung fibroblasts [34,35], a
finding which we also confirmed (Figure 4). Although
bFGF is a milder stimulus for lung fibroblasts than clas-
sical mitogens such as EGF and PDGF [35], exposure
to conditioned media of RV-infected epithelial cells
containing bFGF at much lower levels than our positive
control (approx. 10-fold), resulted in a weaker, as
expected, but nonetheless significant stimulation of
fibroblast proliferation. Notably, we showed that the RV-
induced fibroblast proliferation may be exacerbated in
an atopic asthmatic environment, further reinforcing its
biological significance. Preincubation of RV-infected
conditioned medium with an anti-bFGF antibody
resulted in a partial, yet considerable suppression of the
RV-induced stroma cell proliferation, implying bFGF as
a major mediator. Stimulation of proliferation could be
also attributed, at least in part, to the presence of other
cell-secreted products stabilizing or presenting bFGF to
its receptor, or simply acting in synergism [36]. Indeed,
several other mediators reported to be produced by
bronchial epithelial cells are good candidates as con-
tributors to the remaining fibroproliferative activity of
RV infected CM, including TGF-β, IGF-1, PDGF, and
endothelin. Accordingly, we have recently observed up-
regulation of TGF- β1 activity upon RV-infection [18].
Notably, TGF- β1 presence may act synergistically to
further induce bFGF’s proliferative action in the longer
term [37], further potentiating the proliferative capacity
of bronchial epithelial secretions upon RV infection.In addition to that, RV infection results in stimulation
of MMP activity released by bronchial epithelial cells, in
accordance to recent findings [38]. Increased MMP-9
levels have been detected in BAL fluid [39], hypertonic
saline-induced sputum [39,40] and serum [41], of asth-
matic patients, while sputum [40] and serum [41] levels
have been correlated to disease severity. Apart from
their well known role in extracellular matrix (ECM)
turnover, MMPs of bronchial epithelial origin have been
shown to promote fibroblast proliferation [5], suggesting
a potent profibrotic effect. Moreover, the MMPs have
been shown to activate several secreted cytokines and
growth factors [42], and thus their presence in an acti-
vated form in the epithelial supernatants could further
modulate fibroblast proliferation. Most importantly, pro-
MMP9 may potentiate bFGF bioavailability and action
[43], thus further contributing to the bFGF-mediated re-
modeling features of RV infection. Overall, the RV-
mediated induction of MMP activity released by the
bronchial epithelium can modulate both fibroblast
proliferation and collagen turnover, globally affecting
airway remodeling.
Upon virus infection both systemic and local immune
responses are being elicited, further characterized by a
defective Th1 response in atopic asthma [44]. Indeed,
Korpi-Steiner et al. recently showed that RV-infected
PBMCs produce CXCL10 and CCL2 [32], while we
observed higher IL-10 and lower IFN-γ production from
RV-stimulated PBMC of atopic asthmatic versus normal
subjects [18]. Moreover, RV infection results in a signifi-
cant increase of IL-8 and a statistically insignificant
increase of IL-6 production from PBMC, and a parallel
statistically insignificant TGF-β1 reduction in both
atopic asthmatic and normal subjects [18]. In addition,
macrophages from allergen-sensitized and -challenged
mice, but not control mice, express an array of Th2
cytokines following RV infection [45]. Along these lines,
RV-induced PBMC responses correlate well with lung
function measures in asthma [46]. Accordingly, we
investigated the role of atopy and allergy in modulating
RV-induced bFGF release by bronchial epithelial cells by
pre-exposing the latter to CM, generated by exposure of
PBMC to RV. Using this recently described model [18]
we have previously demonstrated an enhanced RV-
mediated epithelial VEGF induction in the atopic asth-
matic context [15]. The here observed enhanced bFGF
release under the influence of an “atopic asthmatic”
environment may recapitulate the effect of an altered
cytokine profile of RV-infected PBMCs from atopic asth-
matics [18,44]. For instance, elevated IL-8 release upon
RV infection [18] may partly explain the induction of
bFGF production by PBMC-exposed bronchial epithelial
cells, as this chemokine has been shown to induce both
expression and release of bFGF in other settings [47].
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altered immune response in asthma may affect airway
remodeling [1]. In the same setting, future studies exam-
ining the potential effect of mediators released by
allergen- or allergen- plus RV-stimulated PBMCs may
offer additional insight to the role of virus-allergen inter-
actions on lower airways remodeling.
Our in vitro data were confirmed by measuring levels
of bFGF released in the airways following RV-induced
asthma exacerbations. The elevated bFGF in nasal secre-
tions of asthmatic children may represent a link of viral
infections with bFGF and the remodeling process as a
whole. Inclusion of asthmatic children with a virus-
induced exacerbation attributed to other viruses than
RV as well as non-asthmatic children with an upper
respiratory tract infection due to RV would offer add-
itional valid comparisons and their absence represents
a limitation of our study. The increased concentration
of bFGF recorded in the present study could be attribu-
ted to increased production by stroma or inflammatory
cells, as well as release of preformed protein bound to
the ECM. Indeed, both intact and cleaved heparan
sulfate proteoglycan (HSPG) have been shown to bind
and release bFGF in the asthmatic airways. HSPG distri-
bution differs considerably among asthma patients [9],
and HSPG from different patients may respond differen-
tially in releasing bound bFGF. In addition thrombin,
whose levels in the airways of asthmatics may differ
up to 10-fold, can facilitate bFGF release leading to up
to 5-fold differences in bFGF levels [48]. The above
could partially attribute the more robust bFGF increase
observed in 30% of the asthma patients of this study
upon RV infection to differences in ECM composition
and response. Nonetheless, we also showed that the
bronchial epithelium also takes part in bFGF release in
an inducible manner.
An increase of bFGF levels in BAL fluid of asthmatic
patients, also relating to increased vascularity in asth-
matic airways has been reported [7,8]. Increased bFGF
levels in asthmatics as compared to controls even at
baseline status may be attributed to delayed viral clear-
ance, which is prominent in atopic patients [49]. Sus-
tained high levels of such growth factors may play a vital
role in remodeling and collagen turnover processes.
In summary, we demonstrated that in addition to
VEGF production [15,27], RV infection induces bFGF
release by the bronchial epithelium. bFGF may thus
mediate an additional role of RV infection on asthmatic
airway remodeling by stimulating proliferation of stroma
cells, accentuated in the context of an atopic environ-
ment. These findings further support the notion that in
addition to asthma exacerbations, an abnormal response
to viral infection may contribute to the persistence
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